empagliflozin


( Last Updated : September 15, 2022)
Generic Name:
empagliflozin
Project Status:
Active
Therapeutic Area:
Heart failure
Manufacturer:
Boehringer Ingelheim (Canada) Ltd.
Call for patient/clinician input open:
Brand Name:
Jardiance
Project Line:
Reimbursement Review
Project Number:
SR0726-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC

Details


Manufacturer Requested Reimbursement Criteria1:
For the treatment of heart failure in patients with New York Heart Association (NYHA) class II, III, or IV. To be used as an adjunct to standard of care therapy.
Submission Type:
Initial
Fee Schedule:
Schedule A
Tumour Type:
N/A
Indications:
Jardiance is indicated in adults, as an adjunct to standard of care therapy for the treatment of chronic heart failure.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open09-Mar-22
Call for patient/clinician input closed29-Apr-22
Clarification:

- Patient input submission received from the HeartLife Foundation

Submission received06-Apr-22
Submission accepted21-Apr-22
Review initiated22-Apr-22
Draft CADTH review report(s) provided to sponsor for comment07-Jul-22
Deadline for sponsors comments18-Jul-22
CADTH review report(s) and responses to comments provided to sponsor12-Aug-22
Expert committee meeting (initial)24-Aug-22
Draft recommendation issued to sponsor06-Sep-22
Draft recommendation posted for stakeholder feedback15-Sep-22
End of feedback period29-Sep-22